A Phase I/IIa multicentre study in otherwise healthy infants and toddlers hospitalised for and diagnosed with respiratory syncytial virus lower respiratory tract infection, consisting of an open-label lead-in part followed by a double-blind, placebo-contr

A Phase I/IIa multicentre study in otherwise healthy infants and toddlers hospitalised for and diagnosed with respiratory syncytial virus lower respiratory tract infection, consisting of an open-label lead-in part followed by a double-blind, placebo-controlled part, to evaluate the safety, tolerability, and clinical activity of ALX-0171, administered via inhalation, in addition to standard of care

เพณณินาท์ โอเบอร์ดอร์เฟอร์, สัจจะ อิศรางกูร ณ อยุธยา